AbelZeta Email Format
Biotechnology ResearchMaryland, United States51-200 Employees
AbelZeta is a global clinical-stage biopharmaceutical company focused on developing cell-based therapies that leverage the body's immune system to treat cancer and immune-related conditions. Its pipeline centers on approaches using engineered immune cells to target hematologic malignancies, solid tumors, and inflammatory or immunological diseases. The company conducts early-stage clinical work in GMP-enabled facilities at centers of excellence in Rockville, Maryland, and Shanghai, China. Through these efforts, AbelZeta aims to deliver bespoke therapies tailored to individual patients. It operates within the biotechnology research sector, seeking to translate laboratory discoveries into clinical candidates. In January 2026, AbelZeta expanded its collaboration with AstraZeneca to develop and commercialize C-CAR301 in China.